Caitlin A Smith1, Jeremiah J Duby, Garth H Utter, Joseph M Galante, Lynette A Scherer, Carol R Schermer. 1. Caitlin A. Smith, M.D., is General Surgery Resident; Jeremiah J. Duby, Pharm.D., is Assistant Clinical Professor of Pharmacy; Garth H. Utter, M.D., M.Sc., is Associate Professor of Surgery; Joseph M. Galante, M.D., is Assistant Professor of Surgery; Lynette A. Scherer, M.D., is Professor of Surgery; and Carol R. Schermer, M.D., M.P.H., is Professor of Surgery, Department of Surgery, Division of Trauma and Emergency Surgery, and Department of Pharmacy, University of California, Davis, Medical Center, Sacramento.
Abstract
PURPOSE: Results of a study to determine potential cost benefits of substituting an alternative electrolyte solution for 0.9% sodium chloride injection for the initial fluid resuscitation of trauma patients are presented. METHODS: Using data from a randomized clinical trial that compared 24-hour fluid resuscitation outcomes in critically injured trauma patients treated with 0.9% sodium chloride injection and those who received a balanced electrolyte solution (Plasma-Lyte A, Baxter Healthcare), a cost-minimization analysis was performed at a large medical center. The outcomes evaluated included fluid and drug acquisition costs, materials and nurse labor costs, and costs associated with electrolyte replacement. RESULTS: The use of Plasma-Lyte A was associated with a relatively higher fluid acquisition cost but a reduced need for magnesium replacement. During the first 24 hours of hospitalization, 4 of 24 patients (17%) treated with 0.9% sodium chloride injection and none of the patients who received the comparator product (n = 22) required supplemental magnesium. Patients treated with 0.9% sodium chloride injection received a median of 4 g of magnesium (interquartile range [IQR], 2.5-4.0 g), compared with a median of 0 g (IQR 0-2 g) in the comparator group. Taking into account the costs of consumable supplies and nursing labor, the cost-minimization analysis indicated a 24-hour cost differential of $12.35 in favor of Plasma-Lyte A. CONCLUSION: Substitution of Plasma-Lyte A for 0.9% sodium chloride injection for fluid resuscitation during the first 24 hours after traumatic injury was associated with decreased magnesium replacement requirements and a net cost benefit to the institution.
RCT Entities:
PURPOSE: Results of a study to determine potential cost benefits of substituting an alternative electrolyte solution for 0.9% sodium chloride injection for the initial fluid resuscitation of traumapatients are presented. METHODS: Using data from a randomized clinical trial that compared 24-hour fluid resuscitation outcomes in critically injured traumapatients treated with 0.9% sodium chloride injection and those who received a balanced electrolyte solution (Plasma-Lyte A, Baxter Healthcare), a cost-minimization analysis was performed at a large medical center. The outcomes evaluated included fluid and drug acquisition costs, materials and nurse labor costs, and costs associated with electrolyte replacement. RESULTS: The use of Plasma-Lyte A was associated with a relatively higher fluid acquisition cost but a reduced need for magnesium replacement. During the first 24 hours of hospitalization, 4 of 24 patients (17%) treated with 0.9% sodium chloride injection and none of the patients who received the comparator product (n = 22) required supplemental magnesium. Patients treated with 0.9% sodium chloride injection received a median of 4 g of magnesium (interquartile range [IQR], 2.5-4.0 g), compared with a median of 0 g (IQR 0-2 g) in the comparator group. Taking into account the costs of consumable supplies and nursing labor, the cost-minimization analysis indicated a 24-hour cost differential of $12.35 in favor of Plasma-Lyte A. CONCLUSION: Substitution of Plasma-Lyte A for 0.9% sodium chloride injection for fluid resuscitation during the first 24 hours after traumatic injury was associated with decreased magnesium replacement requirements and a net cost benefit to the institution.
Authors: Rolf Rossaint; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund A M Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Jean-Louis Vincent; Donat R Spahn Journal: Crit Care Date: 2016-04-12 Impact factor: 9.097
Authors: Jeffrey D Curran; Paityn Major; Kent Tang; Sean M Bagshaw; Joanna C Dionne; Kusum Menon; Bram Rochwerg Journal: Crit Care Explor Date: 2021-05-14
Authors: Alba M Antequera Martín; Jesus A Barea Mendoza; Alfonso Muriel; Ignacio Sáez; Mario Chico-Fernández; José M Estrada-Lorenzo; Maria N Plana Journal: Cochrane Database Syst Rev Date: 2019-07-19
Authors: Suzanne Laplante; Dilip U Makhija; Sibyl H Munson; Victor S Khangulov; Fred W Peyerl; Scott M Paluszkiewicz; Aditi J Ravindranath; Carol R Schermer Journal: Pharmacoecon Open Date: 2018-09